DEA fourth temporary rule: telemedicine controlled-substance flexibilities through December 31, 2026

Prescribing controlled substances via telemedicine remains under a temporary federal framework. The Drug Enforcement Administration’s fourth temporary extension of COVID-19 telemedicine flexibilities continues specified pathways for prescribing Schedule II–V controlled substances via telemedicine without a prior in-person medical evaluation, subject to the conditions in the temporary rule—through December 31, 2026.

Read the primary texts: the Federal Register notice for the fourth temporary extension and the DEA press release on extending telemedicine flexibilities. This post is an NP-facing briefing only. It is not legal advice, not a protocols manual, and not a substitute for counsel, medical directors, or state board guidance.

What changed (and what stayed temporary)

During the COVID-19 public health emergency, federal flexibilities allowed certain controlled-substance prescribing by telemedicine without the usual prior in-person exam in defined circumstances. Those flexibilities have been extended in successive temporary rules while DEA and HHS work toward a longer-term regulatory structure.

The fourth temporary extension pushes the runway to December 31, 2026. That date matters for clinic policy calendars, telehealth service lines, and controlled-substance workflows—but it is still a temporary bridge. A permanent rule is not final as of the materials cited here; practices should plan for possible further extension, modification, or a different permanent framework without assuming today’s conditions are locked in forever.

Who is affected

• NPs and other DEA-registered practitioners who prescribe Schedule II–V medications in telemedicine models that relied on the COVID-era flexibilities.
• Clinics, behavioral health programs, and primary care telehealth services whose protocols reference the temporary rules.
• Patients who receive ongoing controlled-substance management through telemedicine and need continuity planning before December 31, 2026.
• Compliance, credentialing, and pharmacy partners who must align federal DEA conditions with state telemedicine, controlled-substance, and APRN practice laws.

Holding a DEA registration and an APRN license is not enough by itself: federal and state law still apply together. A state may be stricter than the federal temporary flexibility, or may impose its own telemedicine or PDMP requirements.

What to do now

1. Read the Federal Register temporary rule for the exact conditions, definitions, and limits that apply to your prescribing scenario—do not rely on hallway summaries. 2. Map state law for every state where the patient is located when care is delivered (and where you are authorized to practice). Temporary federal flexibility does not waive state APRN collaboration, supervision, telehealth registration, or controlled-substance rules. 3. Update clinic protocols with the December 31, 2026 horizon, including what happens if a permanent rule issues earlier or if conditions change. 4. Document medical decision-making, telemedicine modality, and identity verification consistent with your organization’s policies and applicable law. 5. Watch DEA/HHS announcements for permanent-rule progress rather than waiting until late 2026 to discover a cliff. 6. Coordinate with pharmacies and EHR e-prescribing settings so workflows match current federal and state requirements.

What this is not

• Not blanket permission to prescribe any controlled substance by video for any patient without meeting the temporary rule’s conditions.
• Not a final permanent telemedicine controlled-substance rule—the extension is explicitly temporary through December 31, 2026.
• Not legal advice, medical advice, or authorization to ignore PDMP, state opioid rules, or payer policies.
• Not an inventory of hour counts, visit frequencies, or drug-specific schedules beyond what the cited federal sources state.

Bookmark the Federal Register fourth temporary extension and the DEA announcement. When you track DEA registration renewals alongside state licenses and CE, CeMe Tracker and the CeMe Tracker blog are useful companions—always verify prescribing authority against primary federal and state sources before you change a telemedicine protocol.